Sensorion and EVEON Unveil Revolutionary Injection System for Delivering Gene Therapy Treatments Directly to the Inner Ear

Sensorion and EVEON have joined forces to design and develop a revolutionary injection system for the delivery of Sensorion’s gene therapy products to the inner ear, with their OTOF-GT product candidate at the forefront. This pioneering clinical-stage biotechnology company specializes in the development of novel therapies to restore, treat, and prevent hearing loss disorders, while EVEON is a designer and manufacturer of custom medical devices for the preparation and delivery of drugs. This collaboration is sure to be a game-changer in the hearing loss treatment field.

Sensorion and EVEON have joined forces to develop treatments for genetic hearing loss that are both effective and patient-friendly. To this end, they are exploring ways to maximize the delivery of gene therapies into the inner ear – a delicate and intricate organ embedded in the temporal bone. With their combined efforts, they are striving to create gene therapies that are safe, effective, and provide a positive patient experience.

Sensorion is thrilled to have collaborated with ENT surgeons and EVEON to create an injection system for secure and successful delivery of our gene therapy candidates. Our delivery system is designed to enable the delivery of our gene therapy products into the inner ear with the objective of bringing back hearing in patients struggling from hereditary monogenic forms of deafness. The efficient and safe administration of gene therapies is paramount, so we need to guarantee an ideal route of injection.

At EVEON, we are delighted to partner with Sensorion, a leading provider of hearing therapeutics. This collaboration showcases the power of our respective technology platforms and allows us to develop custom solutions for delivering novel gene therapies. We are excited to be working together and to see what our unified efforts can achieve.

Sensorion is striving to make a difference for those affected by hereditary monogenic forms of deafness. Through their two gene therapy programs, OTOF-GT and GJB2-GT, they are working to correct deafness caused by mutations of the gene encoding for otoferlin and hearing loss related to mutations in GJB2 gene, respectively. This pioneering research could potentially provide relief for adults and children suffering from hearing loss.

About Sensorion

Sensorion is a groundbreaking clinical-stage biotech company, leading the charge to develop innovative therapies for restoring, treating, and preventing hearing loss disorders – a major global medical need that lacks sufficient solutions. With their cutting-edge research and dedication to the cause, Sensorion is at the forefront of the effort to improve hearing health and quality of life for countless individuals.

Sensorion has crafted an innovative research and development technology platform, allowing it to gain insights into the causes and symptoms of inner ear-related diseases. Through this platform, the company is able to determine the best therapeutic targets and mechanisms of action for drug candidates. Its portfolio includes both small molecule and inner ear gene therapy programs, offering a comprehensive approach to tackling these conditions.

SENS-401 (Arazasetron) is the only clinical-stage product in Sense Bio’s portfolio, currently undergoing a Phase 2 Proof of Concept study. This trial is investigating the potential of SENS-401 in Cisplatin-Induced Ototoxicity (CIO) and, in collaboration with Cochlear Limited, in patients scheduled for cochlear implantation. In January 2022, the company completed a Phase 2 study of SENS-401 in Sudden Sensorineural Hearing Loss (SSNHL), furthering its mission to develop innovative treatments for hearing-related diseases.

Sensorion is actively collaborating with Institut Pasteur to advance genetics for hearing health. The joint efforts are centered around two gene therapy programs with the aim of treating hereditary monogenic forms of deafness. These include OTOF-GT, which targets deafness caused by otoferlin gene mutations, and GJB2-GT, which focuses on hearing loss related to mutations in GJB2 gene. This collaboration has the potential to benefit individuals of all ages who suffer from hearing impairments, while also aiding in the development of new biomarkers to improve diagnosis of these conditions.


EVEON is committed to transforming the therapeutic landscape by designing and developing custom devices that enable practitioners and patients to access advanced treatments with improved compliance and performance. Backed by certifications in ISO13485 and international standards such as EN 62304 and EN 60601-1, EVEON offers customized solutions tailored to the specific needs of its clients, or based on its proprietary Intuity® platform. To further cultivate a vibrant business environment, EVEON is also involved in a French program that brings together diverse companies from various economic fields.

Leave a Comment